"Without this sizable commitment of capi tal and expertise, our path to market would have been inherently delayed. ”What was the $300mil JV with the Chinese for then?
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
